SEC Form 4 · accession 0001140361-18-025378
NRC HEALTH · NRC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John N Nunnelly
Director
Period of report
May 21, 2018
Accepted (ET)
May 23, 2018 · 5:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000070487
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 21, 2018 | M | 12,794 | $14.95 | A | 44,688 | D | |
| Common Stock | May 21, 2018 | F | 5,504 | $34.75 | D | 39,184 | D | |
| Common StockF2 | May 21, 2018 | S | 7,290 | $34.6627 | D | 31,894 | D | |
| Common Stock | May 22, 2018 | M | 10,881 | $14.95 | A | 42,775 | D | |
| Common Stock | May 22, 2018 | F | 4,770 | $34.10 | D | 38,005 | D | |
| Common StockF3 | May 22, 2018 | S | 6,111 | $34.2995 | D | 31,894 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy) | $14.95 | May 21, 2018 | M | 12,794 | D | May 8, 2015 | May 8, 2024 | Common Stock | 12,794 | 20,256 | D |
| Director Stock Option (Right to Buy) | $14.95 | May 22, 2018 | M | 10,881 | D | May 8, 2015 | May 8, 2024 | Common Stock | 10,881 | 9,375 | D |
| Director Stock Option (Right to Buy) | $9.73 | holding | — | — | — | May 6, 2012 | May 6, 2021 | Common Stock | 28,763 | 28,763 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2018.
- F2The price in Column 4 is a weighted average price. The prices actually received ranged from $34.05 to $34.95. The reporting person has provided to the issuer, and will provide to any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.
- F3The price in Column 4 is a weighted average price. The prices actually received ranged from $33.85 to $34.65. The reporting person has provided to the issuer, and will provide to any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.